CD155 immunohistochemical expression in upper tract urothelial carcinoma predicts poor prognosis

Ikeda,Junichi; Ohe,Chisato; Yoshida,Takashi; Saito,Ryoichi; Tsuta,Koji; Kinoshita,Hidefumi

doi:10.3892/ol.2022.13534

CD155 immunohistochemical expression in upper tract urothelial carcinoma predicts poor prognosis

Authors:
- Junichi Ikeda
- Chisato Ohe
- Takashi Yoshida
- Ryoichi Saito
- Koji Tsuta
- Hidefumi Kinoshita
View Affiliations

Affiliations: Department of Pathology, Kansai Medical University, Hirakata, Osaka 573‑1191, Japan, Department of Urology and Andrology, Kansai Medical University, Hirakata, Osaka 573‑1191, Japan
Published online on: September 28, 2022 https://doi.org/10.3892/ol.2022.13534
Article Number: 414

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

A novel immune checkpoint, CD155/T‑cell immunoreceptor with Ig and ITIM domains, has been recognized as a new therapeutic target in addition to conventional immune checkpoints, such as anti‑programmed cell death protein 1/programmed cell death ligand 1 (PD‑L1), for urothelial carcinoma (UC). Fibroblast growth factor receptor (FGFR) is considered another new therapeutic target for UC. As FGFR3‑mutant UC may be associated with decreased T‑cell infiltration, FGFR3 inhibition may facilitate lymphocyte invasion into the tumor microenvironment. Although a combined effect of immune checkpoint inhibitors and FGFR inhibition is expected, the combined expression profiles of CD155, PD‑L1 and FGFR3 have not been evaluated in upper tract UC (UTUC). The present study aimed to investigate the association between CD155 expression and clinicopathological factors in 208 patients with UTUC undergoing radical nephroureterectomy. Furthermore, the expression profiles of CD155, PD‑L1 and FGFR3 were compared. Immunohistochemical analysis was performed using tissue microarray specimens and survival analyses were performed using the Kaplan‑Meier method and the Cox proportional hazards model. High immunohistochemical expression of CD155 was observed in 177 patients (85.1%) and it was associated with advanced pathological stage and lymphovascular invasion. The survival rate was lower among patients with tumors exhibiting high CD155 expression than among those with tumors with low CD155 expression. In addition, multivariate survival analysis revealed that high CD155 expression was an independent prognostic factor for recurrence (hazard ratio=7.32, 95% CI=1.01‑53.35, P=0.049). FGFR3 and immune checkpoint signaling molecules, such as CD155 and PD‑L1, had a weak negative correlation. The present results indicated that the expression of CD155 is a useful marker for predicting the recurrence of UTUC. In addition, the immunohistochemical expression profiles of CD155, PD‑L1 and FGFR3 may further the understanding of the role of FGFR‑targeted therapies in immunotherapy for UTUC.

View Figures

View References

1	Huben RP, Mounzer AM and Murphy GP: Tumor grade and stage as prognostic variables in upper tract urothelial tumors. Cancer. 62:2016–2020. 1988. View Article : Google Scholar : PubMed/NCBI
2	Margulis V, Shariat SF, Matin SF, Kamat AM, Zigeuner R, Kikuchi E, Lotan Y, Weizer A, Raman JD and Wood CG; Upper Tract Urothelial Carcinoma Collaboration The Upper Tract Urothelial Carcinoma Collaboration, : Outcomes of radical nephroureterectomy: A series from the upper tract urothelial carcinoma collaboration. Cancer. 115:1224–1233. 2009. View Article : Google Scholar : PubMed/NCBI
3	Califano G, Ouzaid I, Verze P, Hermieu JF, Mirone V and Xylinas E: Immune checkpoint inhibition in upper tract urothelial carcinoma. World J Urol. 39:1357–1367. 2021. View Article : Google Scholar : PubMed/NCBI
4	Qin S, Xu L, Yi M, Yu S, Wu K and Luo S: Novel immune checkpoint targets: Moving beyond PD-1 and CTLA-4. Mol Cancer. 18:1552019. View Article : Google Scholar : PubMed/NCBI
5	Anderson AC, Joller N and Kuchroo VK: Lag-3, Tim-3, and TIGIT: Co-inhibitory receptors with specialized functions in immune regulation. Immunity. 44:989–1004. 2016. View Article : Google Scholar : PubMed/NCBI
6	Stanietsky N, Rovis TL, Glasner A, Seidel E, Tsukerman P, Yamin R, Enk J, Jonjic S and Mandelboim O: Mouse TIGIT inhibits NK-cell cytotoxicity upon interaction with PVR. Eur J Immunol. 43:2138–2150. 2013. View Article : Google Scholar : PubMed/NCBI
7	Nishiwada S, Sho M, Yasuda S, Shimada K, Yamato I, Akahori T, Kinoshita S, Nagai M, Konishi N and Nakajima Y: Clinical significance of CD155 expression in human pancreatic cancer. Anticancer Res. 35:2287–2297. 2015.PubMed/NCBI
8	Zhang J, Zhu Y, Wang Q, Kong Y, Sheng H, Guo J, Xu J and Dai B: Poliovirus receptor CD155 is up-regulated in muscle-invasive bladder cancer and predicts poor prognosis. Urol Oncol. 38:41.e11–41.e18. 2020. View Article : Google Scholar : PubMed/NCBI
9	Xu Y, Cui G, Jiang Z, Li N and Zhang X: Survival analysis with regard to PD-L1 and CD155 expression in human small cell lung cancer and a comparison with associated receptors. Oncol Lett. 17:2960–2968. 2019.PubMed/NCBI
10	Atsumi S, Matsumine A, Toyoda H, Niimi R, Iino T and Sudo A: Prognostic significance of CD155 mRNA expression in soft tissue sarcomas. Oncol Lett. 5:1771–1776. 2013. View Article : Google Scholar : PubMed/NCBI
11	Sloan KE, Eustace BK, Stewart JK, Zehetmeier C, Torella C, Simeone M, Roy JE, Unger C, Louis DN, Ilag LL and Jay DG: CD155/PVR plays a key role in cell motility during tumor cell invasion and migration. BMC Cancer. 4:732004. View Article : Google Scholar : PubMed/NCBI
12	Chauvin JM and Zarour HM: TIGIT in cancer immunotherapy. J Immunother Cancer. 8:e0009572020. View Article : Google Scholar : PubMed/NCBI
13	Sanchez-Correa B, Valhondo I, Hassouneh F, Lopez-Sejas N, Pera A, Bergua JM, Arcos MJ, Bañas H, Casas-Avilés I, Durán E, et al: DNAM-1 and the TIGIT/PVRIG/TACTILE axis: Novel immune checkpoints for natural killer cell-based cancer immunotherapy. Cancers (Basel). 11:8772019. View Article : Google Scholar : PubMed/NCBI
14	Kim YS, Kim K, Kwon GY, Lee SJ and Park SH: Fibroblast growth factor receptor 3 (FGFR3) aberrations in muscle-invasive urothelial carcinoma. BMC Urol. 18:682018. View Article : Google Scholar : PubMed/NCBI
15	Turner N and Grose R: Fibroblast growth factor signalling: From development to cancer. Nat Rev Cancer. 10:116–129. 2010. View Article : Google Scholar : PubMed/NCBI
16	Wang L, Gong Y, Saci A, Szabo PM, Martini A, Necchi A, Siefker-Radtke A, Pal S, Plimack ER, Sfakianos JP, et al: Fibroblast growth factor receptor 3 alterations and response to PD-1/PD-L1 blockade in patients with metastatic urothelial cancer. Eur Urol. 76:599–603. 2019. View Article : Google Scholar : PubMed/NCBI
17	Kacew A and Sweis RF: FGFR3 alterations in the era of immunotherapy for urothelial bladder cancer. Front Immunol. 11:5752582020. View Article : Google Scholar : PubMed/NCBI
18	Chen S, Zhang N, Shao J, Wang T and Wang X: Multi-omics perspective on the tumor microenvironment based on PD-L1 and CD8 T-Cell infiltration in urothelial cancer. J Cancer. 10:697–707. 2019. View Article : Google Scholar : PubMed/NCBI
19	Moch H, Humphrey PA, Ulbright TM and Reuter VE: WHO classification of tumours of the urinary system and male genital organs. WHO Classification of Tumours. 8. 4th edition. International Agency for Research on Cancer; Lyon: 2016
20	Brierley J, Gospodarowicz MK and Wittekind C: TNM classification of malignant tumours. 8th edition. John Wiley & Sons Inc.; Hoboken, NJ: 2017
21	Ikeda J, Ohe C, Yoshida T, Kuroda N, Saito R, Kinoshita H, Tsuta K and Matsuda T: Comprehensive pathological assessment of histological subtypes, molecular subtypes based on immunohistochemistry, and tumor-associated immune cell status in muscle-invasive bladder cancer. Pathol Int. 71:173–182. 2021. View Article : Google Scholar : PubMed/NCBI
22	Kanda Y: Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 48:452–458. 2013. View Article : Google Scholar : PubMed/NCBI
23	Molfetta R, Zitti B, Lecce M, Milito ND, Stabile H, Fionda C, Cippitelli M, Gismondi A, Santoni A and Paolini R: CD155: A multi-functional molecule in tumor progression. Int J Mol Sci. 21:9222020. View Article : Google Scholar : PubMed/NCBI
24	Bowers JR, Readler JM, Sharma P and Excoffon KJDA: Poliovirus receptor: More than a simple viral receptor. Virus Res. 242:1–6. 2017. View Article : Google Scholar : PubMed/NCBI
25	Rikitake Y, Mandai K and Takai Y: The role of nectins in different types of cell-cell adhesion. J Cell Sci. 125:3713–3722. 2012. View Article : Google Scholar : PubMed/NCBI
26	Gao J, Zheng Q, Xin N, Wang W and Zhao C: CD155, an onco-immunologic molecule in human tumors. Cancer Sci. 108:1934–1938. 2017. View Article : Google Scholar : PubMed/NCBI
27	Shariat SF, Youssef RF, Gupta A, Chade DC, Karakiewicz PI, Isbarn H, Jeldres C, Sagalowsky AI, Ashfaq R and Lotan Y: Association of angiogenesis related markers with bladder cancer outcomes and other molecular markers. J Urol. 183:1744–1750. 2010. View Article : Google Scholar : PubMed/NCBI
28	Kinugasa M, Amano H, Satomi-Kobayashi S, Nakayama K, Miyata M, Kubo Y, Nagamatsu Y, Kurogane Y, Kureha F, Yamana S, et al: Necl-5/poliovirus receptor interacts with VEGFR2 and regulates VEGF-induced angiogenesis. Circ Res. 110:716–726. 2012. View Article : Google Scholar : PubMed/NCBI
29	Luke JJ, Bao R, Sweis RF, Spranger S and Gajewski TF: WNT/β-catenin pathway activation correlates with immune exclusion across human cancers. Clin Cancer Res. 25:3074–3083. 2019. View Article : Google Scholar : PubMed/NCBI
30	Xue G, Romano E, Massi D and Mandalà M: Wnt/β-catenin signaling in melanoma: Preclinical rationale and novel therapeutic insights. Cancer Treat Rev. 49:1–12. 2016. View Article : Google Scholar : PubMed/NCBI
31	Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT and Gajewski TF: Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med. 5:200ra1162013. View Article : Google Scholar : PubMed/NCBI
32	Sweis RF, Spranger S, Bao R, Paner GP, Stadler WM, Steinberg G and Gajewski TF: Molecular drivers of the non-T-cell-inflamed tumor microenvironment in urothelial bladder cancer. Cancer Immunol Res. 4:563–568. 2016. View Article : Google Scholar : PubMed/NCBI
33	Buchtova M, Oralova V, Aklian A, Masek J, Vesela I, Ouyang Z, Obadalova T, Konecna Z, Spoustova T, Pospisilova T, et al: Fibroblast growth factor and canonical WNT/β-catenin signaling cooperate in suppression of chondrocyte differentiation in experimental models of FGFR signaling in cartilage. Biochim Biophys Acta. 1852:839–850. 2015. View Article : Google Scholar : PubMed/NCBI
34	Xiao JF, Caliri AW, Duex JE and Theodorescu D: Targetable pathways in advanced bladder cancer: FGFR signaling. Cancers (Basel). 13:48912021. View Article : Google Scholar : PubMed/NCBI